Jazz Pharmaceuticals, Inc. (JAZZ) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 9, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 3, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the JAZZ SEC filings page.
Jazz Pharmaceuticals, Inc. (JAZZ) reported $4.6B in revenue over the twelve months to Jun 30, 2026, up 12.6% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Cash generation remains durable even as FY2025 earnings reverse, while lower debt leaves the business less leveraged but less liquid.
In FY2025, operating cash flow was$1.36B while net income was a net loss of$356M , separating reported earnings from cash economics. Free cash flow remained$1.30B against capital expenditures of$58.8M , suggesting the earnings reversal included substantial noncash or timing effects rather than a comparable cash deterioration.
The reversal from FY2024's
Debt-to-equity fell from 1.5x in FY2024 to 1.0x in FY2025, indicating a less debt-dependent capital structure. Yet the current ratio fell from 4.5x to 1.9x as current liabilities more than doubled, so improved solvency came with a thinner short-term liquidity buffer.
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Jazz Pharmaceuticals, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Jazz Pharmaceuticals, Inc. has an operating margin of -10.1%, meaning the company loses $10 on every $100 of revenue. This results in a profitability score of 38/100. This is down from 17.6% the prior year.
Jazz Pharmaceuticals, Inc.'s revenue grew a modest 4.9% year-over-year to $4.3B. This slow but positive growth earns a score of 52/100.
Jazz Pharmaceuticals, Inc. has a moderate D/E ratio of 1.00. This balance of debt and equity financing earns a leverage score of 47/100.
Jazz Pharmaceuticals, Inc.'s current ratio of 1.86 indicates adequate short-term liquidity, earning a score of 55/100. The company can meet its near-term obligations, though with limited headroom.
Jazz Pharmaceuticals, Inc. converts 30.4% of revenue into free cash flow ($1.3B). This strong cash generation earns a score of 95/100.
Jazz Pharmaceuticals, Inc. posts a -8.3% return on equity (ROE), meaning it loses $8 for every $100 of shareholders' equity. This results in a returns score of 29/100. This is down from 13.7% the prior year.
Jazz Pharmaceuticals, Inc. scores 1.68, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($14.2B) relative to total liabilities ($7.3B). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Jazz Pharmaceuticals, Inc. passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
Jazz Pharmaceuticals, Inc. reported a net loss of $356.1M while generating $1.4B in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Jazz Pharmaceuticals, Inc. reported an operating loss of $430.2M against $195.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Jazz Pharmaceuticals, Inc. generated $1.2B in revenue in Q2 2026. This represents an increase of 15.5% from the same quarter a year earlier. Against the prior quarter it is up 13.0%.
Jazz Pharmaceuticals, Inc.'s EBITDA was $427.3M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 183.4% from the same quarter a year earlier. Against the prior quarter it is down 17.5%.
Jazz Pharmaceuticals, Inc. reported $192.8M in net income in Q2 2026. This represents an increase of 126.8% from the same quarter a year earlier. Against the prior quarter it is down 34.2%.
Jazz Pharmaceuticals, Inc. earned $2.78 per diluted share (EPS) in Q2 2026. This represents an increase of 123.7% from the same quarter a year earlier. Against the prior quarter it is down 37.2%.
Cash & Balance Sheet
Jazz Pharmaceuticals, Inc. generated $397.6M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 423.8% from the same quarter a year earlier. Against the prior quarter it is up 2.3%.
Jazz Pharmaceuticals, Inc. held $1.6B in cash against $3.3B in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Jazz Pharmaceuticals, Inc.'s operating margin was 20.5% in Q2 2026, reflecting core business profitability. This is up 86.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 11.0 percentage points.
Jazz Pharmaceuticals, Inc.'s net profit margin was 16.0% in Q2 2026, showing the share of revenue converted to profit. This is up 84.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 11.5 percentage points.
Jazz Pharmaceuticals, Inc.'s ROE was 4.0% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 23.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.4 percentage points.
Not reported for Q2 2026.
Capital Allocation
Jazz Pharmaceuticals, Inc. invested $207.5M in research and development in Q2 2026. This represents an increase of 9.3% from the same quarter a year earlier. Against the prior quarter it is up 5.9%.
Jazz Pharmaceuticals, Inc. invested $18.1M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 40.3% from the same quarter a year earlier. Against the prior quarter it is down 8.1%.
Not reported for Q2 2026.
JAZZ Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2B+15.5% | $1.1B+19.1% | $1.2B+10.1% | $1.1B+6.7% | $1.0B+2.1% | $897.8M-0.5% | $1.1B+7.5% | $1.1B+8.5% |
| R&D Expenses | $207.5M+9.3% | $196.0M+8.5% | $213.9M-11.0% | $198.2M-0.9% | $189.9M-14.0% | $180.7M-18.9% | $240.5M+11.0% | $199.9M-14.7% |
| SG&A Expenses | $389.2M+8.6% | $352.7M-31.4% | $406.2M+10.0% | $530.6M+62.9% | $358.4M+5.9% | $514.0M+46.1% | $369.3M-6.8% | $325.8M+5.7% |
| Operating Income | $248.2M+136.2% | $336.6M+702.1% | $254.6M+33.4% | $57.5M-77.9% | -$686.4M-444.2% | -$55.9M-184.4% | $190.8M+55.7% | $260.2M+50.9% |
| EBITDA | $427.3M+183.4% | $518.0M+375.7% | -$220.9M+17.6% | $235.8M-44.6% | -$512.4M-241.4% | $108.9M-52.6% | -$268.1M+17.9% | $425.4M+27.0% |
| Interest Expense | $37.1M-21.7% | $39.9M-25.7% | $45.4M-11.5% | $48.6M-17.2% | $47.4M-23.6% | $53.7M-18.8% | $51.3M+127.5% | $58.7M-17.9% |
| Income Tax | $18.1M+205.2% | $6.1M+134.3% | $5.0M+108.6% | -$242.4M-1568.1% | -$17.2M+43.9% | -$17.8M-252.5% | -$57.9M-75.0% | -$14.5M+69.2% |
| Net Income | $192.8M+126.8% | $293.1M+416.9% | $203.4M+6.4% | $251.4M+16.9% | -$718.5M-526.2% | -$92.5M-532.8% | $191.1M+103.0% | $215.1M+46.5% |
| EPS (Basic) | $3.05+126.0% | $4.73+411.2% | $3.34+6.7% | $4.14+18.3% | -$11.74-538.1% | -$1.52-560.9% | $3.13+108.7% | $3.50+50.2% |
| EPS (Diluted) | $2.78+123.7% | $4.43+391.4% | $3.34+10.6% | $4.08+19.3% | -$11.74-571.5% | -$1.52-560.9% | $3.02+111.2% | $3.42+59.8% |
| Diluted Shares (Avg) | 69M+13.4% | 66M+8.4% | N/A | 62M-2.5% | 61M-12.1% | 61M-2.5% | N/A | 63M-11.4% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
JAZZ Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $11.1B+1.2% | $11.9B+2.8% | $11.7B-2.9% | $11.4B-7.3% | $10.9B-3.7% | $11.5B+1.8% | $12.0B+5.4% | $12.3B+9.4% |
| Current Assets | $4.0B+18.4% | $4.6B+11.0% | $4.2B-10.0% | $3.8B-14.5% | $3.4B-9.0% | $4.1B+16.6% | $4.6B+34.7% | $4.4B+35.3% |
| Cash & Equivalents | $1.6B+36.1% | $1.8B-0.9% | $1.4B-42.3% | $1.3B-40.2% | $1.2B-12.2% | $1.9B+29.0% | $2.4B+60.2% | $2.2B+66.1% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $443.0M-12.3% | $437.5M-11.2% | $417.0M-13.2% | $483.1M-10.4% | $505.0M-6.9% | $492.8M-14.6% | $480.4M-19.5% | $539.3M-11.9% |
| Accounts Receivable | $880.9M+23.4% | $836.3M+28.1% | $830.7M+15.9% | $764.4M+5.6% | $714.0M+2.3% | $653.0M-7.7% | $716.8M+1.6% | $723.6M+15.3% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $1.8B-2.4% | $1.8B+2.6% | $1.8B+6.6% | $1.8B+1.3% | $1.8B+6.2% | $1.8B+1.2% | $1.7B-2.1% | $1.8B+5.8% |
| Total Liabilities | $6.3B-13.2% | $7.3B-0.4% | $7.3B-7.3% | $7.4B-8.5% | $7.2B-4.8% | $7.4B-3.5% | $7.9B+3.4% | $8.1B+4.8% |
| Current Liabilities | $2.2B+7.7% | $2.2B+83.8% | $2.2B+115.9% | $2.3B+120.8% | $2.1B+33.1% | $1.2B-21.7% | $1.0B-32.4% | $1.0B-34.5% |
| Non-Current Liabilities | $4.0B-21.6% | $5.1B-17.2% | $5.1B-25.9% | $5.1B-27.4% | $5.2B-14.5% | $6.1B+1.1% | $6.9B+12.4% | $7.1B+14.9% |
| Long-Term Debt | $3.3B-23.1% | $4.3B-19.0% | $4.3B-28.8% | $4.3B-28.8% | $4.3B-15.0% | $5.3B+4.5% | $6.1B+19.0% | $6.1B+19.0% |
| Total Equity | $4.8B+29.6% | $4.5B+8.6% | $4.3B+5.5% | $4.0B-5.1% | $3.7B-1.5% | $4.2B+12.9% | $4.1B+9.5% | $4.2B+19.5% |
| Retained Earnings | $1.1B+491.7% | $939.2M-9.2% | $646.1M-42.7% | $442.7M-52.7% | $191.3M-78.0% | $1.0B+19.8% | $1.1B+28.3% | $936.2M+5.9% |
JAZZ Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $415.7M+368.1% | $408.2M-5.0% | $362.5M-9.0% | $474.7M+19.0% | $88.8M-73.2% | $429.8M+60.8% | $398.6M+138.2% | $398.7M+29.8% |
| Depreciation & Amortization | $179.1M+2.9% | $181.4M+10.1% | -$475.5M-3.6% | $178.3M+7.9% | $174.0M+6.7% | $164.8M+0.9% | -$458.9M-2.2% | $165.2M+1.6% |
| Stock-Based Compensation | $73.3M+13.6% | $74.5M+10.0% | N/A | $88.1M+47.5% | $64.5M+13.8% | $67.7M+10.2% | N/A | $59.8M+6.5% |
| Capital Expenditures | $18.1M+40.3% | $19.7M+41.7% | $16.7M+25.9% | $15.2M+41.1% | $12.9M+81.9% | $13.9M+101.3% | $13.3M+31.5% | $10.8M+150.9% |
| Free Cash Flow | $397.6M+423.8% | $388.5M-6.6% | $345.8M-10.3% | $459.4M+18.4% | $75.9M-76.6% | $415.9M+59.8% | $385.3M+145.0% | $388.0M+28.1% |
| Investing Cash Flow | $354.9M+155.4% | $123.1M+172.8% | -$372.2M-92.5% | -$327.8M-253.1% | -$641.0M-149.3% | -$169.0M+37.8% | -$193.3M-289.9% | $214.1M+222.8% |
| Financing Cash Flow | -$994.5M-699.4% | -$78.5M+90.4% | $75.4M+1011.7% | -$10.9M-104.4% | -$124.4M+22.8% | -$813.5M-1338.5% | -$8.3M+91.8% | $246.4M+413.9% |
| Share Buybacks | N/A | N/A | $0 | $23K-100.0% | N/A | N/A | $0-100.0% | $150.0M+101.7% |
Not reported in any period shown, so not listed: Dividends Paid.
JAZZ Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | 20.5%+86.2pp | 31.5%+37.7pp | 21.3%+3.7pp | 5.1%-19.6pp | -65.6%-85.1pp | -6.2%-13.6pp | 17.5%+5.4pp | 24.7%+6.9pp |
| Net Margin | 16.0%+84.7pp | 27.4%+37.7pp | 17.0%-0.6pp | 22.3%+1.9pp | -68.7%-85.2pp | -10.3%-8.7pp | 17.6%+8.3pp | 20.4%+5.3pp |
| Return on Equity | 4.0%+23.4pp | 6.5%+8.7pp | 4.7%0.0pp | 6.3%+1.2pp | -19.4%-23.9pp | -2.2%-1.8pp | 4.7%+2.1pp | 5.2%+1.0pp |
| Return on Assets | 1.7%+8.3pp | 2.5%+3.3pp | 1.7%+0.1pp | 2.2%+0.5pp | -6.6%-8.0pp | -0.8%-0.7pp | 1.6%+0.8pp | 1.8%+0.4pp |
| Current Ratio | 1.78+0.2x | 2.04-1.3x | 1.86-2.6x | 1.65-2.6x | 1.62-0.7x | 3.38+1.1x | 4.46+2.2x | 4.26+2.2x |
| Debt-to-Equity | 0.69-0.5x | 0.95-0.3x | 1.00-0.5x | 1.09-0.4x | 1.17-0.2x | 1.28-0.1x | 1.48+0.1x | 1.460.0x |
| Asset Turnover | 0.110.0x | 0.090.0x | 0.100.0x | 0.100.0x | 0.100.0x | 0.080.0x | 0.090.0x | 0.090.0x |
| FCF Margin | 32.9%+25.7pp | 36.4%-10.0pp | 28.9%-6.6pp | 40.8%+4.0pp | 7.3%-24.4pp | 46.3%+17.5pp | 35.4%+19.9pp | 36.8%+5.6pp |
Not reported in any period shown, so not listed: Gross Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Jazz Pharmaceuticals, Inc. JAZZ | FY2025 | $4.3B | -$356.1M | -8.3% | $14.2B | 53/100 |
| Legend Biotech Corporation LEGN | FY2025 | $1.0B | -$296.8M | -28.8% | $3.6B | 41/100 |
| Verona Pharma plc VRNA | FY2024 | $42.3M | -$173.4M | N/A | $9.2B | 60/100 |
| Bio-Techne Corp. TECH | FY2026 | $1.2B | $181.9M | 15.0% | $11.4B | 74/100 |
| Corcept Therapeutics Inc. CORT | FY2025 | $761.4M | $99.7M | 13.1% | $12.8B | 77/100 |
Where Jazz Pharmaceuticals, Inc. Ranks
Frequently Asked Questions
What is Jazz Pharmaceuticals, Inc.'s annual revenue?
Jazz Pharmaceuticals, Inc. (JAZZ) reported $4.3B in total revenue for fiscal year 2025. This represents a 4.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Jazz Pharmaceuticals, Inc.'s revenue growing?
Jazz Pharmaceuticals, Inc. (JAZZ) revenue grew by 4.9% year-over-year, from $4.1B to $4.3B in fiscal year 2025.
Is Jazz Pharmaceuticals, Inc. profitable?
No, Jazz Pharmaceuticals, Inc. (JAZZ) reported a net income of -$356.1M in fiscal year 2025, with a net profit margin of -8.3%.
What is Jazz Pharmaceuticals, Inc.'s EBITDA?
Jazz Pharmaceuticals, Inc. (JAZZ) had EBITDA of -$388.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Jazz Pharmaceuticals, Inc. have?
As of fiscal year 2025, Jazz Pharmaceuticals, Inc. (JAZZ) had $1.4B in cash and equivalents against $4.3B in long-term debt.
What is Jazz Pharmaceuticals, Inc.'s operating margin?
Jazz Pharmaceuticals, Inc. (JAZZ) had an operating margin of -10.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Jazz Pharmaceuticals, Inc.'s net profit margin?
Jazz Pharmaceuticals, Inc. (JAZZ) had a net profit margin of -8.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Jazz Pharmaceuticals, Inc.'s return on equity (ROE)?
Jazz Pharmaceuticals, Inc. (JAZZ) has a return on equity of -8.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Jazz Pharmaceuticals, Inc.'s free cash flow?
Jazz Pharmaceuticals, Inc. (JAZZ) generated $1.3B in free cash flow during fiscal year 2025. This represents a -4.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Jazz Pharmaceuticals, Inc.'s operating cash flow?
Jazz Pharmaceuticals, Inc. (JAZZ) generated $1.4B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Jazz Pharmaceuticals, Inc.'s total assets?
Jazz Pharmaceuticals, Inc. (JAZZ) had $11.7B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Jazz Pharmaceuticals, Inc.'s capital expenditures?
Jazz Pharmaceuticals, Inc. (JAZZ) invested $58.8M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Jazz Pharmaceuticals, Inc. spend on research and development?
Jazz Pharmaceuticals, Inc. (JAZZ) invested $782.7M in research and development during fiscal year 2025.
What is Jazz Pharmaceuticals, Inc.'s current ratio?
Jazz Pharmaceuticals, Inc. (JAZZ) had a current ratio of 1.86 as of fiscal year 2025, which is generally considered healthy.
What is Jazz Pharmaceuticals, Inc.'s debt-to-equity ratio?
Jazz Pharmaceuticals, Inc. (JAZZ) had a debt-to-equity ratio of 1.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Jazz Pharmaceuticals, Inc.'s return on assets (ROA)?
Jazz Pharmaceuticals, Inc. (JAZZ) had a return on assets of -3.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Jazz Pharmaceuticals, Inc.'s P/E ratio?
Jazz Pharmaceuticals, Inc. (JAZZ) trades at 15.1x earnings, its market capitalization divided by net income of $940.8M net income, trailing 12 months to June 30, 2026. The market capitalization is $14.2B as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Jazz Pharmaceuticals, Inc.'s price-to-sales ratio?
Jazz Pharmaceuticals, Inc. (JAZZ) trades at 3.1x sales, its market capitalization divided by revenue of $4.6B revenue, trailing 12 months to June 30, 2026. The market capitalization is $14.2B as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Jazz Pharmaceuticals, Inc.'s Altman Z-Score?
Jazz Pharmaceuticals, Inc. (JAZZ) has an Altman Z-Score of 1.68, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Jazz Pharmaceuticals, Inc.'s Piotroski F-Score?
Jazz Pharmaceuticals, Inc. (JAZZ) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Jazz Pharmaceuticals, Inc.'s earnings high quality?
Jazz Pharmaceuticals, Inc. (JAZZ) reported a net loss of $356.1M while generating $1.4B in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Jazz Pharmaceuticals, Inc. cover its interest payments?
Jazz Pharmaceuticals, Inc. (JAZZ) reported an operating loss of $430.2M against $195.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Jazz Pharmaceuticals, Inc.?
Jazz Pharmaceuticals, Inc. (JAZZ) scores 53 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.